Skip to content

CavatermTM for Idiopathic Functional Menometrorraghia

Evolution of Symptoms After Treatment With System CavatermTM for Idiopathic Functional Menometrorraghia Contraceptive Implants

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07205146
Acronym
CAVATERM
Enrollment
20
Registered
2025-10-03
Start date
2025-06-01
Completion date
2025-08-01
Last updated
2025-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cavaterm™ System

Keywords

Cavaterm™ system, idiopathic functional menometrorrhagia

Brief summary

The prevalence of menometrorrhagia is estimated at 11% to 13% in the general population and increases with age to reach 24% in 36-40 year olds. It is the leading cause of gynecological consultations. Considered benign, menometrorrhagia is responsible for anemia and impaired quality of life. It is the most common cause of iron deficiency anemia in premenopausal women. The etiology of menometrorrhagia is varied. The main causes of menometrorrhagia are organic causes, iatrogenic causes, coagulopathies, hypothyroidism, and endometrial atrophy. In the majority of cases, no underlying pathology is found; they are then called functional idiopathic. This is a diagnosis of exclusion. In idiopathic functional menometrorrhagia, the first-line treatment is medical. In the event of failure of medical treatment (in 50% of cases), in women who do not wish to maintain their reproductive possibilities, surgical treatment may be considered. The Cavaterm™ system is a balloon-assisted endometrial ablation device. Treatment with Cavaterm™ involves removing the endometrium using a minimally invasive technique. The procedure is short-term and outpatient. In this study, we aim to evaluate the Cavaterm™ system for the treatment of idiopathic functional menometrorrhagia.

Interventions

OTHERmenometrorrhagia

rate of menometrorrhagia at 2 months after treatment

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inclusion Criteria \* : * women over 18 * patient who benefited from treatment with the Cavaterm™ system for idiopathic functional menometrorrhagia * treatment between January 2024 and December 2024 * person having expressed his non-opposition *

Exclusion criteria

\* : * inability to understand the information given * person deprived of liberty * person under guardianship

Design outcomes

Primary

MeasureTime frameDescription
menometrorrhagiaat 2 months after treatmentrate of menometrorrhagia at 2 months after treatment

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026